CVRx is a commercial-stage medical device company. Co.'s proprietary platform technology, Barostim, is designed to utilize the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure (HF) and other cardiovascular diseases. Co.'s product, Barostim, is commercially available neuromodulation device indicated to improve symptoms for patients with HF with reduced Ejection Fraction. Barostim provides Baroreflex Activation Therapy by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate the cardiovascular function. The CVRX YTD return is shown above.
The YTD Return on the CVRX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CVRX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CVRX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|